Real-time Estimate
Cboe BZX
10:16:52 2024-05-02 am EDT
|
5-day change
|
1st Jan Change
|
2.895
USD
|
+4.51%
|
|
+39.02%
|
-15.18%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
678.2
|
425.7
|
455.5
|
321.3
|
268.5
|
-
|
-
|
Enterprise Value (EV)
1 |
678.2
|
425.7
|
455.5
|
321.3
|
268.5
|
268.5
|
268.5
|
P/E ratio
|
-3.04
x
|
-3.39
x
|
-5.96
x
|
-2.45
x
|
-1.64
x
|
-1.56
x
|
-1.68
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
13.6
x
|
3.49
x
|
4.97
x
|
5.07
x
|
20.1
x
|
48.4
x
|
EV / Revenue
|
-
|
13.6
x
|
3.49
x
|
4.97
x
|
5.07
x
|
20.1
x
|
48.4
x
|
EV / EBITDA
|
-5,470,709
x
|
-3,110,265
x
|
-8,316,569
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-5.21
x
|
-4.05
x
|
-14.8
x
|
-3.37
x
|
-3.73
x
|
-1.59
x
|
-1.45
x
|
FCF Yield
|
-19.2%
|
-24.7%
|
-6.74%
|
-29.6%
|
-26.8%
|
-62.9%
|
-68.9%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
61,820
|
62,506
|
85,949
|
95,624
|
96,928
|
-
|
-
|
Reference price
2 |
10.97
|
6.810
|
5.300
|
3.360
|
2.770
|
2.770
|
2.770
|
Announcement Date
|
3/11/21
|
3/10/22
|
3/9/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
31.24
|
130.5
|
64.7
|
52.92
|
13.33
|
5.55
|
EBITDA
|
-
|
-124
|
-136.9
|
-54.77
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-126.5
|
-141.4
|
-59.95
|
-129.5
|
-173.2
|
-216.6
|
-233.3
|
Operating Margin
|
-
|
-
|
-452.69%
|
-45.94%
|
-200.15%
|
-327.39%
|
-1,624.69%
|
-4,202.99%
|
Earnings before Tax (EBT)
1 |
-
|
-129.8
|
-125
|
-63.46
|
-123.3
|
-179.1
|
-225.3
|
-237.1
|
Net income
1 |
-
|
-129.8
|
-125
|
-64
|
-123.4
|
-179.1
|
-225.3
|
-237.1
|
Net margin
|
-
|
-
|
-400.07%
|
-49.05%
|
-190.76%
|
-338.48%
|
-1,689.51%
|
-4,271.36%
|
EPS
2 |
-5.500
|
-3.610
|
-2.010
|
-0.8900
|
-1.370
|
-1.686
|
-1.780
|
-1.650
|
Free Cash Flow
1 |
-
|
-130.2
|
-105.2
|
-30.7
|
-95.23
|
-72
|
-169
|
-185
|
FCF margin
|
-
|
-
|
-336.7%
|
-23.52%
|
-147.18%
|
-136.06%
|
-1,267.5%
|
-3,333.33%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/19/20
|
3/11/21
|
3/10/22
|
3/9/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
31.24
|
1.435
|
2.7
|
116.3
|
10.05
|
10.34
|
20.01
|
9.352
|
25
|
11.67
|
13.75
|
13.75
|
13.75
|
7.5
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-41.59
|
-17.48
|
-56.96
|
-41.54
|
71.78
|
-33.22
|
-39.52
|
-27.86
|
-36.22
|
-25.91
|
-41.71
|
-40.86
|
-41.6
|
-44.12
|
-54.5
|
Operating Margin
|
-
|
-55.95%
|
-3,969.41%
|
-1,538.7%
|
61.72%
|
-330.52%
|
-382.06%
|
-139.18%
|
-387.32%
|
-103.66%
|
-357.51%
|
-297.13%
|
-302.58%
|
-320.91%
|
-726.67%
|
Earnings before Tax (EBT)
1 |
-42.42
|
1.469
|
-58.06
|
-43.04
|
70.66
|
-33.03
|
-38.85
|
-27.46
|
-31.67
|
-25.35
|
-42.38
|
-41.58
|
-42.38
|
-44.95
|
-57.25
|
Net income
1 |
-42.42
|
1.469
|
-58.06
|
-43.04
|
70.41
|
-33.32
|
-38.85
|
-27.46
|
-31.78
|
-25.35
|
-42.38
|
-41.58
|
-42.38
|
-44.95
|
-57.25
|
Net margin
|
-
|
4.7%
|
-4,045.78%
|
-1,593.93%
|
60.54%
|
-331.49%
|
-375.59%
|
-137.19%
|
-339.8%
|
-101.42%
|
-363.3%
|
-302.4%
|
-308.22%
|
-326.91%
|
-763.33%
|
EPS
2 |
-0.6800
|
0.0200
|
-0.9300
|
-0.6900
|
0.9200
|
-0.3900
|
-0.4500
|
-0.3200
|
-0.3500
|
-0.2700
|
-0.4200
|
-0.4175
|
-0.4000
|
-0.3950
|
-0.4300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
3/10/22
|
5/12/22
|
8/11/22
|
11/10/22
|
3/9/23
|
5/9/23
|
8/8/23
|
11/9/23
|
3/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-130
|
-105
|
-30.7
|
-95.2
|
-72
|
-169
|
-185
|
ROE (net income / shareholders' equity)
|
-
|
-231%
|
-59.8%
|
-37.2%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-3.150
|
-1.650
|
-0.3700
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
16.9
|
2.63
|
3.92
|
3.07
|
4
|
4.05
|
4.4
|
Capex / Sales
|
-
|
-
|
8.43%
|
3.01%
|
4.74%
|
7.56%
|
30.38%
|
79.28%
|
Announcement Date
|
6/19/20
|
3/11/21
|
3/10/22
|
3/9/23
|
3/7/24
|
-
|
-
|
-
|
Last Close Price
2.77
USD Average target price
14
USD Spread / Average Target +405.42% Consensus |
1st Jan change
|
Capi.
|
---|
| -15.18% | 268M | | -1.58% | 104B | | +3.22% | 97.47B | | +5.44% | 22.25B | | -13.96% | 21.68B | | -9.40% | 18.2B | | -39.98% | 17.02B | | -10.75% | 16.36B | | +7.05% | 14.39B | | +39.45% | 12.37B |
Bio Therapeutic Drugs
|